Clinical Policy Bulletin: Bone-anchored Hearing Aid
Aetna considers implantable bone-anchored hearing aids (BAHAs) or temporal bone stimulators medically necessary prosthetics for persons aged 5 years and older with a unilateral or bilateral conductive or mixed conductive and sensorineural hearing loss who have any of the following conditions, where the condition prevents restoration of hearing using a conventional air-conductive hearing aid and who meet the audiologic criteria below:
Congenital or surgically induced malformations of the external ear canal or middle ear (such as aural atresia); or
Dermatitis of the external ear, including hypersensitivity reactions to ear moulds used in air conduction hearing aids; or
Hearing loss secondary to otosclerosis in persons who can not undergo stapedectomy; or
Severe chronic external otitis or otitis media; or
Tumors of the external ear canal and/or tympanic cavity; or
Other conditions in which an air-conduction hearing aid is contraindicated.
Unilateral implant: Conductive or mixed (conductive and sensorineural) hearing loss with pure tone average bone conduction threshold (measured at 0.5, 1, 2, and 3 kHz) less than or equal to 45 dB HL (BAHA Divino, BAHA BP100), 55 dB HL (BAHA Intenso, Cochlear Baha 3 Power [BP110]) or 65 dB HL (BAHA Cordelle II).
Bilateral implant: Moderate-to-severe bilateral symmetric conductive or mixed (conductive and sensorineural) hearing loss, meeting above-listed bone conduction thresholds in both ears. Symmetric bone conduction threshold is defined as less than:
10 dB average (measured at 0.5, 1, 2 and 4 kHz) or less than 15 dB at individual frequencies (BAHA Divino, BAHA BP100); or
10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies (BAHA Cordelle II, BAHA Intenso).
Aetna considers an implantable BAHA for conductive or mixed hearing loss experimental and investigational when criteria are not met because of insufficient evidence in the peer-reviewed published medical literature.
Aetna considers the use of an implantable BAHA medically necessary in persons with unilateral sensorineural hearing loss (single-sided deafness, i.e., deafness in one ear while the other ear has normal hearing). Aetna considers the use of an implantable BAHA experimental and investigational for bilateral pure sensorineural hearing loss, and for all other indications becuase its effectiveness for indications other than the ones listed above has not been established.
Note: Aetna follows Medicare rules in considering osseointegrated implants, such as implantable BAHAs and temporal bone stimulators, as prosthetics. Medicare considers as prosthetics "osseointegrated implants, i.e., devices implanted in the skull that replace the function of the middle ear and provide mechanical energy to the cochlea via a mechanical transducer."
The bone-anchored hearing aid (BAHA) is a bone-conduction hearing aid that allows direct bone-conduction through a titanium implant and has become available as an acceptable alternative if an air-conduction hearing aid is contraindicated. The BAHA transmits sound vibrations through the skull bone via a skin-penetrating titanium implant, and then are further transmitted to the cochlea, bypassing the middle ear. Several clinical trials have shown its efficacy in patients with a conductive or mixed hearing loss. Indications for the BAHA include hearing loss from congenital ear problems, chronic suppurative otitis media, and in some cases otosclerosis as a third treatment option in those who can not or will not undergo stapedectomy. A second group of potential candidates are patients who suffer from an almost instantaneous skin reaction to any kind of ear mold. In some patients, the benefits are not necessarily those in hearing ability but relate to cosmetic or comfort improvements. Pre-operative assessment of the size of the air-bone gap is of some help to predict whether speech recognition may improve or deteriorate with the BAHA compared with the air-conduction hearing aid.
There is evidence in the peer-reviewed published medical literature to support the use of BAHAs over air conduction hearing aids, however, most of the studies have focused on individuals who suffer from single sided deafness, with unilateral sensorineural deafness in one ear while the other ear has normal hearing. The Food and Drug Administration (FDA) has cleared for marketing the bone anchored hearing aid for individuals aged 5 years and older who have conductive or mixed hearing loss and for patients with sensorineural deafness in one ear and normal hearing in the other based on a 510(k) application. Such clearance was granted based on a determination that the BAHA was substantially equivalent to a contralateral routing of sound (CROS) air conduction hearing aid. A unilateral implant is used for individuals with unilateral conductive or mixed hearing loss and for unilateral sensorineural hearing loss. According to the FDA-approved indications, a bilateral implant is intended for patients with bilaterally symmetric moderate to severe conductive or mixed hearing loss.
In a recently published meta-analysis of the evidence for BAHA for single-sided deafness, Baguley and colleagues (2006) explained that acquired unilateral sensorineural hearing loss reduces the ability to localize sounds and to discriminate in background noise. Four controlled trials have been conducted to determine the benefit of contralateral BAHAs over CROS hearing aids and over the unaided condition. Speech discrimination in noise and subjective questionnaire measures of auditory abilities showed an advantage for BAHA over CROS and over unaided conditions. However, these studies did not find significant improvements in auditory localization with either aid. The investigators noted that these conclusions should be interpreted with caution because these studies have material shortfalls: (i) the BAHA was always trialled after the CROS aid; (ii) CROS aids were only trialled for 4 weeks; (iii) none used any measure of hearing handicap when selecting subjects; (iv) 2 studies have a bias in terms of patient selection; (v) all studies were under-powered; and (vi) double reporting of patients occurred (Baugley et al, 2006).
Priwin et al (2007) investigated (i) whether bilateral BAHAs in children with conductive bilateral hearing loss provided additional hearing benefits, (ii) the effects of unilateral hearing aids in children with conductive unilateral hearing loss, and (iii) the auditory problems of children with conductive unilateral or bilateral hearing loss. This prospective case series included 22 children with either conductive unilateral hearing loss (unaided or with unilateral hearing aid) or conductive bilateral hearing loss (with unilateral or bilateral BAHAs) and 15 controls. The investigators tested baseline audiometry, tone thresholds in a sound field, and speech recognition in noise and sound localization with and without unilateral and bilateral hearing aids. Two self-assessment questionnaires were completed. The investigators reported 2 problem areas in the children with hearing impairment: (i) reactions to sounds, and (ii) intelligibility of speech. An additional BAHA in the children with bilateral hearing loss resulted in a tendency to have improved hearing in terms of better sound localization and speech recognition in noise. Fitting of unilateral hearing aids in the children with unilateral hearing loss gave some supplementary benefit in terms of better speech recognition in noise but no positive effect on ability to localize sound could be detected. Even so, all children fitted with hearing aids, either unilaterally or bilaterally, reported a positive outcome with their devices in the self-assessment questionnaire. The investigators concluded that the fitting of bilateral BAHAs in children with bilateral hearing loss and of a single-sided hearing aid in children with unilateral hearing loss appears to have some supplementary audiological benefits and also renders high patient satisfaction.
When suggested indications for treatment with the BAHA system are followed, the success rate is very high. The improved quality of life reported by the patients is a combination of improved quality of sound (warble tone threshold, speech reception threshold, and discrimination in noise), improved comfort, and relief from middle ear and ear canal disease occasioned by conventional hearing aids.
An assessment of the BAHA device by the Institute for Clinical Effectiveness and Health Policy (Pichon-Rivere et al, 2009) concluded that there is evidence that BAHA is useful for people with conductive-type hearing loss who can not undergo surgery or who have contraindications or adverse effects to hearing aids. If implantation is used, it should be implanted to patients over 5 years old and by specially trained staff in an operating room. Evidence comes, however, from observational studies, many of which include a few participants.
Although no longer marketed, the Audiant (Medtronic Xomed, Inc., Jacksonville, FL) Bone Conductor, also known as the temporal bone stimulator, is an FDA-approved implanted device with an external processor that uses transcutaneous inductive electromagnetic energy to cause vibration of an implanted titanium magnet screwed into the temporal bone. Like the currently marketed BAHA device, the Audiant Bone Conductor is also based on a bone conduction concept, and is also indicated for persons with conductive or mixed conductive and sensorineural hearing loss who have conditions that prevent restoration of hearing using a conventional air-conductive hearing aid.
Hol et al (2010) evaluated the effectiveness of 3 CROS hearing aids in adults (n = 10 with unilateral inner ear deafness and normal hearing in the contralateral ear: (i) the CROS hearing aid, (ii) the completely in the canal hearing aid, and (iii) the BAHA CROS (BAHA). Each of the 3 hearing aids was tried in a random order for a period of 8 weeks. Audiometric performance, including speech-in-noise, directional hearing and subjective benefit were measured after each trial period, using the Abbreviated Profile of Hearing Aid Benefit (APHAB), SSQ and single-sided deafness questionnaire. Sound localization performance was essentially at chance level in all 4 conditions. Mixed results were seen on the other patient outcome measures that alternated in favor of one of the 3 CROS devices. After the trial, 3 patients chose to be fitted with the BAHA CROS and 1 with the conventional CROS. The authors concluded that most of the patients experienced some degree of benefit with each of the 3 hearing aids. Preference for one of the 3 hearing aids was independent of the order in which they were tried. It would be worthwhile to formulate selection criteria; still, the authors recommended that all patients with unilateral inner ear deafness should be offered a trial with at least the BAHA CROS.
de Wolf and colleagues (2011a) stated that a study performed in the 1990s with analog linear hearing aids showed that in patients with mixed hearing loss and an air-bone gap that exceeded 25 to 30 dB, speech perception was better with a BAHA than with a conventional behind-the-ear (BTE) device. The objective of the present study was to examine if this conclusion applies to today's digital BTEs with feedback cancellation and whether the cross-over point still occurs at an air-bone gap of 25 to 30 dB. Experienced unilateral BAHA users with the latest digital Baha processors were fitted with a powerful BTE with feedback cancellation. After an acclimatization period of 4 weeks, aided thresholds and speech recognition scores were determined and compared to those recorded previously with the BAHA. To obtain patients' opinions, a disability-specific questionnaire was used. Participants comprised 16 subjects with bilateral mixed hearing loss. Audiometric and speech recognition data showed similar trends to those described previously, but the cross-over point had shifted to an air-bone gap of 30 to 35 dB. In the questionnaire, the BTE was rated higher than the BaHA, except by the patients with an air-bone gap that exceeded an average of 45 dB. The authors concluded that in patients with mixed hearing loss whose air-bone gap exceeded 35 dB, speech recognition is likely to be better with a BAHA than with a BTE. Thus, the BAHA should receive greater consideration when mixed hearing loss is combined with a significant air-bone gap, even when there are no contraindications for BTEs.
de Wolf and colleagues (2011b) evaluated the benefits of a BAHA in the daily lives of hearing-impaired children. A total of 38 BAHA users with a minimum age of 4 years at BAHA fitting and 1 to 4 years of use were divided into groups with bilateral conductive or mixed hearing loss and either normal cognition or mental disability and a group with unilateral conductive hearing loss. Main outcome measures included scores on the Glasgow Children's Benefit Inventory, APHAB, and Health Utilities Index Mark 3. The Glasgow Children's Benefit Inventory showed a subjective overall benefit of +32, +16, and +26 in the 3 groups (on a scale of -100 to +100). The APHAB also showed an overall mean benefit in the groups. On an individual level, a clinically significant benefit was reported by more children in the group with bilateral hearing loss and normal cognition (7 patients [70 %]) than in the unilateral hearing loss group (4 patients [27 %]). Overall mean health utility scores and disability index scores on the Health Utility Index Mark 3 were comparable among the 3 groups. The authors concluded that overall, BAHA fitting can be considered effective and beneficial in children with bilateral or unilateral hearing loss.
Table: Usual medically necessary frequency of replacement for BAHA parts
72 per 6 months
1 per year
1 per 5 years
Adapted from: Wisconsin Department of Health and Family Services, 2005.
Auditory osseointegrated device abutment, any length, replacement only
Other HCPCS codes related to the CPB:
Services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes
Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment [excluded under plans that exclude coverage of hearing aids]
Speech therapy, in the home, per diem
V5008 - V5299
ICD-9 codes covered if selection criteria are met:
Malignant neoplasm of auditory tube, middle ear, and mastoid air cells
Malignant neoplasm of head, face and neck
Malignant neoplasm of skin of ear and external auditory canal
Benign neoplasm of nasal cavities, middle ear, and accessory sinuses
Benign neoplasm of head, face, and neck
Benign neoplasm of ear and external auditory canal
Carcinoma in situ of ear and external auditory canal
Acquired deformities of auricle or pinna [surgically induced malformations of external ear canal or middle ear]
Chronic serous otitis media, simple or unspecified [severe]
Chronic mucoid otitis media [severe]
Other and unspecified chronic nonsuppurative otitis media [severe]
Chronic atticoantral suppurative otitis media [severe]
Unspecified chronic suppurative otitis media [severe]
Unspecified otitis media [chronic severe]
387.0 - 387.9
Otosclerosis [causing hearing loss in persons who cannot undergo stapedectomy]
389.00 - 389.08
Conductive hearing loss
Sensorineural hearing loss, unilateral
389.20 - 389.22
Mixed conductive and sensorineural hearing loss
Other atopic dermatitis and related conditions
692.0 - 692.6, 692.81692.83 - 692.9
Contact dermatitis and other eczema [external ear/hypersensitivity reactions]
Other anomalies of external ear with impairment of hearing [congenital malformations of external ear canal]
Anomaly of middle ear, except ossicles [congenital malformations of middle ear]
Anomalies of ear ossicles [congenital malformations of middle ear]
Unspecified anomaly of ear [congenital malformations of external ear canal or middle ear]
ICD-9 codes not covered for indications listed in the CPB:
389.10 - 389.14, 389.16 - 389.18
Sensorineural hearing loss [other than unilateral]
The above policy is based on the following references:
Hakansson BE, Carlsson PU, Tjellstrom A, et al. The bone-anchored hearing aid: Principal design and audiometric results. Ear Nose Throat J. 1994;73(9):670-675.
Tjellstrom A, Hakansson B. The bone-anchored hearing aid. Design principles, indications, and long- term clinical results. Otolaryngol Clin North Am. 1995;28(1):53-72.
Snik AF, Mylanus EA, Cremers CW. Bone-anchored hearing aids in patients with sensorineural hearing loss and persistent otitis externa. Clin Otolaryngol. 1995;20(1):31-35.
Browning GG, Gatehouse S. Estimation of the benefit of bone-anchored hearing aids. Ann Otol Rhinol Laryngol. 1994;103(11):872-878.
Cooper HR, Burrell SP, Powell RH, et al. The Birmingham bone anchored hearing aid programme: Referrals, selection, rehabilitation, philosophy and adult results. J Laryngol Otol Suppl. 1996;21:13-20.
Niehaus HH, Helms J, Muller J. Are implantable hearing devices really necessary? Ear Nose Throat J. 1995;74(4):271-274, 276.
Powell RH, Burrell SP, Cooper HR, et al. The Birmingham bone anchored hearing aid programme: Paediatric experience and results. J Laryngol Otol Suppl. 1996;21:21-29.
Burrell SP, Cooper HC, Proops DW. The bone anchored hearing aid--the third option for otosclerosis. J Laryngol Otol Suppl. 1996;21:31-37.
Macnamara M, Phillips D, Proops DW. The bone anchored hearing aid (BAHA) in chronic suppurative otitis media (CSOM). J Laryngol Otol Suppl. 1996;21:38-40.
Granstrom G, Tjellstrom A. The bone-anchored hearing aid (BAHA) in children with auricular malformations. Ear Nose Throat J. 1997;76(4):238-240, 242, 244-247.
Mylanus EA, van der Pouw KC, Snik AF, et al. Intraindividual comparison of the bone-anchored hearing aid and air- conduction hearing aids. Arch Otolaryngol Head Neck Surg. 1998;124(3):271-276.
Wazen JJ, Caruso M, Tjellstrom A. Long-term results with the titanium bone-anchored hearing aid: The U.S. experience. Am J Otol. 1998;19(6):737-741.
Tjellstrom A, Hakansson B, Granstrom G. Bone-anchored hearing aids: Current status in adults and children. Otolaryngol Clin North Am. 2001;34(2):337-364.
Snik AF, Mylanus EA, Cremers CW. The bone-anchored hearing aid: A solution for previously unresolved otologic problems. Otolaryngol Clin North Am. 2001;34(2):365-372.
Cooper TJ, Tomlinson J, Sutton J, et al. The use of bone anchored hearing aids. Guidance Note for Purchasers. Sheffield, UK: Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield; 1997.
UK National Health Service, Cambridgeshire and Peterborough Public Health Network. Bone anchored hearing aids (BAHAs). Policy. Cambridgeshire, UK: Cambridgeshire Health Authority Board; February 27, 2002.
Spitzer JB, Soha NG, Wazen JJ. Evolving applications in the use of bone-anchored hearing aids. Am J Audiology. 2002;11:96-103.
National Deaf Children's Society (NDCS). Quality standards in bone anchored hearing aids for children and young people. London, UK: NDCS; July 2003.
U.S. Food and Drug Administration (FDA). Branemark Bone Anchored Hearing Aid (BAHA). Summary of Safety and Effectiveness. 510(k) No. K021837. Rockville, MD: FDA; June 1, 2002.
Niparko JK, Cox KM, Lustig LR. Comparison of the bone anchored hearing aid implantable hearing device with contralateral routing of offside signal amplification in the rehabilitation of unilateral deafness. Otol Neurotol. 2003;24(1):73-78.
Wazem JJ, Spitzer JB, Ghossaini SN, et al. Transcranial contralateral cochlear stimulation in unilateral deafness. Otolaryngol Head Neck Surg. 2003;129:248-254.
Wazen JJ, Spitzer J, Ghossaini SN, et al. Results of the bone-anchored hearing aid in unilateral hearing loss. Laryngoscope. 2001;111(6):955-958.
Stenfelt S, Hakansson B, Jonsson R, Granstrom G. A bone-anchored hearing aid for patients with pure sensorineural hearing impairment: A pilot study. Scand Audiol. 2000;29(3):175-185.
McLarnon CM, Davison T, Johnson IJ. Bone-anchored hearing aid: Comparison of benefit by patient subgroups. Laryngoscope. 2004;114(5):942-944.
Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat. Bone anchored hearing aid (BAHA). Health Technology Scientific Literature Review. Toronto, ON: Ontario Ministry of Health and Long-Term Care; September 2002. Available at: http://www.health.gov.on.ca/english/providers/program/. Accessed August 4, 2004.
Priwin C, Granstrom G. The bone-anchored hearing aid in children: A surgical and questionnaire follow-up study. Otolaryngol Head Neck Surg. 2005;132(4):559-565.
Hol MK, Snik AF, Mylanus EA, Cremers CW. Does the bone-anchored hearing aid have a complementary effect on audiological and subjective outcomes in patients with unilateral conductive hearing loss? Audiol Neurootol. 2005;10(3):159-168.
UK National Health Service (NHS), National Library for Health. Knowledge update: Hearing aid provision and rehabilitation. Specialist Library for ENT and Audiology. London, UK: NHS; April 2006. Available at: www.library.nhs.uk/SpecialistLibraries/ Download.aspx?resID=124002. Accessed May 30, 2006.
Bergeron F. Bone-anchored hearing aid. AETMIS 06-05. Summary. Montreal, QC: Agence D’Evaluation des Technologies et des Modes D’Intervention en Santé (AETMIS); May 2006.
Parrella A, Mundy L. Bone anchored hearing aid (BAHA). Horizon Scanning Prioritising Summary - Volume 8. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); 2005.
Baguley DM, Bird J, Humphriss RL, Prevost AT. The evidence base for the application of contralateral bone anchored hearing aids in acquired unilateral sensorineural hearing loss in adults. Clin Otolaryngol. 2006;31(1):6-14.
Davids T, Gordon KA, Clutton D, Papsin BC. Bone-anchored hearing aids in infants and children younger than 5 years. Arch Otolaryngol Head Neck Surg. 2007;133(1):51-55.
Clark M, Mierzwinski-Urban M. Bone anchored hearing aid in adults. Health Technology Inquiry Service. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); September 28, 2007.
Wisconsin Department of Health and Family Services. Replacement parts for cochlear implant and bone-anchored hearing devices. Attachment 3. Wisconsin Medicaid and BadgerCare Update. No. 2005-20. Madison, WI: Wisconsin Department of Health and Family Services; March 2005. Available at: http://dhs.wisconsin.gov/medicaid/updates/2005/2005pdfs/2005-20.pdf. Accessed July 29, 2008.
U.S. Food and Drug Administration (FDA) 510(k). Branemark Bone Anchored Hearing Aid (BAHA) System. Summary of Safety and Effectiveness. 510(k) No. K984162. Rockville, MD: FDA; June 28, 1999. Available at: http://www.fda.gov/cdrh/pdf/k984162.pdf. Accessed on October 27, 2008.
U.S. Food and Drug Administration (FDA) 510(k). Bilateral fitting of BAHA. Summary of Safety and Effectiveness. 510(k) No. K011438. Rockville, MD: FDA; July 23, 2001. Available at: http://www.fda.gov/cdrh/pdf/k011438.pdf. Accessed on October 27, 2008.
U.S. Food and Drug Administration (FDA). BAHA Divino. Summary of Safety and Effectiveness. 510(k) No. K042017. Rockville, MD: FDA; August 26, 2004. Available at: http://www.fda.gov/cdrh/pdf4/k042017.pdf. Accessed on October 27, 2008.
U.S. Food and Drug Administration (FDA). BAHA Cordelle II. Summary of Safety and Effectiveness. 510(k) No. K080363. Rockville, MD: FDA; April 10, 2008. Available at: http://www.fda.gov/cdrh/pdf8/K080363.pdf. Accessed on October 27, 2008.
U.S. Food and Drug Administration (FDA). BAHA Intenso. Summary of Safety and Effectiveness. 510(k) No. K081606. Rockville, MD: FDA; August 28, 2008. Available at: http://www.fda.gov/cdrh/pdf8/K081606.pdf. Accessed on October 27, 2008.
Priwin C, Jönsson R, Hultcrantz M, et al. BAHA in children and adolescents with unilateral or bilateral conductive hearing loss: A study of outcome. Int J Pediatr Otorhinolaryngol. 2007;71(1):135-145.
Centers for Medicare & Medicaid Services (CMS). Hearing aids and auditory implants. Medicare Benefit Policy Manual, Ch. 16 - General Exclusions from Coverage, Sec. 100 (Rev. 39; Issued: 11-10-05; Effective: 11-10-05; Implementation: 12-12-05). Baltimore, MD: CMS; 2005. Available at: http://www.cms.hhs.gov/manuals/downloads/bp102c16.pdf. Accessed January 6, 2008.
Verhaegen VJ, Mulder JJ, Mylanus EA, et al. Profound mixed hearing loss: Bone-anchored hearing aid system or cochlear implant? Ann Otol Rhinol Laryngol. 2009;118(10):693-697.
Pichon-Riviere A, Augustovski F, Garcia Marti S, et al. BAHA devices in hypoacusia [summary]. IRR No. 171. Buenos Aires, Argentina: Institute for Clinical Effectiveness and Health Policy (IECS); 2009.
Christensen L, Richter GT, Dornhoffer JL. Update on bone-anchored hearing aids in pediatric patients with profound unilateral sensorineural hearing loss. Arch Otolaryngol Head Neck Surg. 2010;136(2):175-177.
Health Technology Inquiry Service (HTIS). Completely-in-the-canal and bone anchored hearing aids: A review of the clinical effectiveness and cost-effectiveness. Health Technology Assessment (HTA). Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); March 4, 2010.
Hol MK, Kunst SJ, Snik AF, Cremers CW. Pilot study on the effectiveness of the conventional CROS, the transcranial CROS and the BAHA transcranial CROS in adults with unilateral inner ear deafness. Eur Arch Otorhinolaryngol. 2010;267(6):889-896.
de Wolf MJ, Hendrix S, Cremers CW, Snik AF. Better performance with bone-anchored hearing aid than acoustic devices in patients with severe air-bone gap. Laryngoscope. 2011(a);121(3):613-616.
de Wolf MJ, Hol MK, Mylanus EA, et al. Benefit and quality of life after bone-anchored hearing aid fitting in children with unilateral or bilateral hearing impairment. Arch Otolaryngol Head Neck Surg. 2011(b);137(2):130-138.
Colquitt JL, Loveman E, Baguley DM, et al. Bone-anchored hearing aids for people with bilateral hearing impairment: A systematic review. Clin Otolaryngol. 2011;36(5):419-441.
Colquitt JL, Jones J, Harris P, et al. Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: A systematic review and economic evaluation. Health Technol Assess. 2011;15(26):1-200, iii-iv.
Olsen SØ, Glad H, Nielsen LH. Comparison of two bone anchored hearing instruments: BP100 and Ponto Pro. Int J Audiol. 2011;50(12):920-928.
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.